Targeted oncology NuVue focuses on liver, pancreatic, and hard-to-treat soft-tissue cancers with diagnostic and targeted therapeutic capabilities. Sales opportunity: position integrated diagnostic and drug-delivery systems to cancer centers handling these tumor types.

Site-specific therapy Therapeutics aim to deliver drugs and thermal effects directly into tumors using minimal systemic dosage. Sales opportunity: highlight reduced systemic toxicity and potential for improved patient quality of life to oncologists and hospital procurement teams.

Diagnostic integration Real-time needle visualization and precise site marking during procedures enable tighter imaging workflows. Sales opportunity: bundle with interventional radiology equipment suppliers and imaging centers seeking enhanced biopsy accuracy.

Early-stage traction Company currently has minimal revenue and a small team, indicating a need for partnerships and pilots with larger players to validate the platform. Sales opportunity: pursue co-development or clinical collaboration deals with large pharma, medtech, or contract research organizations.

Expansion potential Integrated diagnostic-therapeutic platform targets soft-tissue cancers broadly, suggesting scalable opportunities across hospitals and cancer centers. Sales opportunity: propose phased market entry, starting with high-volume centers treating liver and pancreatic cancers, then expand to other soft-tissue indications.